Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 2;28(5):903–914. doi: 10.1158/1078-0432.CCR-21-2547

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. ORR rate (A), best reduction from baseline in the SLD with pembrolizumab monotherapy (B) and acalabrutinib + pembrolizumab combination therapy (C), progression-free survival (D), and overall survival (E) by the treatment group. CR, complete response; ORR, overall response rate; PR, partial response; SLD, sum of longest diameters. — ORR rate (A), best reduction from baseline in the SLD with pembrolizumab monotherapy (B) and acalabrutinib + pembrolizumab combination therapy (C), progression-free survival (D), and overall survival (E) by the treatment group. CR, complete response; ORR, overall response rate; PR, partial response; SLD, sum of longest diameters.